more accurate and prompt responses.
|REPORT||T&R Biofab Announces Research Collaboration for the Development of a 3D Bio-printed Soft Tissue Scaffold||DATE : 2020.02.06||VIEW : 1419|
T&R Biofab (246710, CEO: Wonsoo Yun), a leading 3D bioprinting company, signed a research collaboration agreement with Ethicon, Inc., part of the Johnson & Johnson Medical Devices Companies, to develop a 3D bio-printed soft tissue scaffold.
This collaboration aims to develop innovative soft tissue regeneration/repair products that are differentiated from conventional products in the market based on T&R Biofab’s platform technology using polymer, in situ extracellular extra cellular matrix (ECM) protein(s) and 3D bioprinting. Ethicon shall have the option to commercially exploit the 3D bio-printing technology from this collaboration exclusively, under terms to be negotiated subsequently. The execution of the research collaboration is being managed by the Johnson & Johnson 3D Printing Center. The transaction was facilitated by Johnson & Johnson Innovation, Asia Pacific.
3D bio-printed soft tissue scaffolds can potentially provide support to repair, elevate, and/or reinforce anatomical and structural deficiencies where weakness or voids exist. Potential uses and applications may include wound closure, wound patches, hernia repair, hand surgery, tendon repair, reinforcement of soft tissue in plastic and/or reconstructive surgery, repair of fascial defects, and general soft tissue reconstruction.
Dr. Wonsoo Yun, CEO of T&R Biofab, said, “We would like to use this opportunity as a stepping stone to generate synergy through the joint R&D agreement with Ethicon, Inc.”
About T&R Biofab
T&R Biofab is a biotech company founded in 2013. T&R has developed and commercialized bioresorbable medical devices and bio-inks and actively is actively researching for organoids (artificial mini-organs) and 3D-printed cell therapeutics, using 3D bioprinting technology, a major innovation for the 4th Industrial Revolution.
|Prev ▲||T&R Biofab, obtained license to commercialize (sale) "iPSC-based cardiomyocytes||2020.09.11|
|Next ▼||T&R Biofab received additional approval for Bio-absorbable Mesh||2018.11.21|